BioPharma Resources

Drug Trial Radar · NCT07025915

A Phase 1 Mass Balance Study of [¹⁴C]SSS17 in Healthy Chinese Males

A Mass Balance Study of [14C]SSS17 in Healthy Chinese Male Subjects

Last checked: Nov 19, 2026Latest source record: Jun 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

6

Planned (sponsor's estimate)

Start

Jun 2025

Primary completion

Jul 2025

Study completion Jul 2025

Sponsor

Sponsor type
Industry
First posted
Jun 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study aims to evaluate the absorption, metabolism, and excretion of a single oral dose of \[¹⁴C\]SSS17 in healthy adult Chinese male subjects, elucidating its overall pharmacokinetic profile in humans to provide essential information for its rational clinical use.

Conditions

  • Healthy Subjects (HS)

Interventions

  • [14C]SSS17Drug

    single oral dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cumulative excretion rate of radioactivity in excreta (urine, feces) and total radioactivity (urine and feces)Time frame: up to Day 22
  2. CmaxTime frame: up to day22
  3. TmaxTime frame: up to Day22

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.